BRIDGEWATER, N.J., Jan. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023 at 4:30 p.m. PT (7:30 p.m. ET).
The presentation and question and answer session will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$74.27 |
Daily Change: | -0.39 -0.52 |
Daily Volume: | 1,120,666 |
Market Cap: | US$12.760B |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB